Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. more
Time Frame | NVO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.13% | -3.39% | -3.47% |
1-Month Return | 6.16% | -3.25% | -0.29% |
3-Month Return | -19.76% | -11.61% | 4.5% |
6-Month Return | -24.74% | -5.89% | 6.91% |
1-Year Return | 7.05% | 2.65% | 23.79% |
3-Year Return | 104.69% | 0.56% | 28.43% |
5-Year Return | 272.77% | 34.63% | 83.64% |
10-Year Return | 377.3% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 122.02B | 126.95B | 140.80B | 176.95B | 232.26B | [{"date":"2019-12-31","value":52.54,"profit":true},{"date":"2020-12-31","value":54.66,"profit":true},{"date":"2021-12-31","value":60.62,"profit":true},{"date":"2022-12-31","value":76.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 20.09B | 20.93B | 23.66B | 28.45B | 35.77B | [{"date":"2019-12-31","value":56.17,"profit":true},{"date":"2020-12-31","value":58.53,"profit":true},{"date":"2021-12-31","value":66.15,"profit":true},{"date":"2022-12-31","value":79.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 101.93B | 106.01B | 117.14B | 148.51B | 196.50B | [{"date":"2019-12-31","value":51.88,"profit":true},{"date":"2020-12-31","value":53.95,"profit":true},{"date":"2021-12-31","value":59.62,"profit":true},{"date":"2022-12-31","value":75.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 83.54% | 83.51% | 83.20% | 83.92% | 84.60% | [{"date":"2019-12-31","value":98.74,"profit":true},{"date":"2020-12-31","value":98.71,"profit":true},{"date":"2021-12-31","value":98.34,"profit":true},{"date":"2022-12-31","value":99.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 49.45B | 51.89B | 58.50B | 73.70B | 93.92B | [{"date":"2019-12-31","value":52.65,"profit":true},{"date":"2020-12-31","value":55.25,"profit":true},{"date":"2021-12-31","value":62.28,"profit":true},{"date":"2022-12-31","value":78.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 52.48B | 54.13B | 58.64B | 74.81B | 102.57B | [{"date":"2019-12-31","value":51.17,"profit":true},{"date":"2020-12-31","value":52.77,"profit":true},{"date":"2021-12-31","value":57.17,"profit":true},{"date":"2022-12-31","value":72.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (4.37B) | (1.20B) | 256.00M | (6.07B) | 2.43B | [{"date":"2019-12-31","value":-179.67,"profit":false},{"date":"2020-12-31","value":-49.34,"profit":false},{"date":"2021-12-31","value":10.53,"profit":true},{"date":"2022-12-31","value":-249.67,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 48.55B | 53.13B | 59.08B | 69.06B | 104.67B | [{"date":"2019-12-31","value":46.38,"profit":true},{"date":"2020-12-31","value":50.76,"profit":true},{"date":"2021-12-31","value":56.44,"profit":true},{"date":"2022-12-31","value":65.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 9.60B | 10.99B | 11.32B | 13.54B | 20.99B | [{"date":"2019-12-31","value":45.74,"profit":true},{"date":"2020-12-31","value":52.37,"profit":true},{"date":"2021-12-31","value":53.94,"profit":true},{"date":"2022-12-31","value":64.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | [{"date":"2019-12-31","value":46.55,"profit":true},{"date":"2020-12-31","value":50.35,"profit":true},{"date":"2021-12-31","value":57.07,"profit":true},{"date":"2022-12-31","value":66.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | [{"date":"2019-12-31","value":46.55,"profit":true},{"date":"2020-12-31","value":50.35,"profit":true},{"date":"2021-12-31","value":57.07,"profit":true},{"date":"2022-12-31","value":66.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 38.95B | 42.14B | 47.76B | 55.52B | 83.68B | [{"date":"2019-12-31","value":46.55,"profit":true},{"date":"2020-12-31","value":50.35,"profit":true},{"date":"2021-12-31","value":57.07,"profit":true},{"date":"2022-12-31","value":66.35,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 1.22 | 1.39 | 1.64 | 1.73 | 2.74 | [{"date":"2019-12-31","value":44.61,"profit":true},{"date":"2020-12-31","value":50.86,"profit":true},{"date":"2021-12-31","value":59.82,"profit":true},{"date":"2022-12-31","value":63.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
NVO | |
---|---|
Cash Ratio | 0.36 |
Current Ratio | 0.94 |
Quick Ratio | 0.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NVO | |
---|---|
ROA (LTM) | 21.47% |
ROE (LTM) | 88.73% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NVO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.70 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.30 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NVO | |
---|---|
Trailing PE | 36.12 |
Forward PE | 27.55 |
P/S (TTM) | 1.80 |
P/B | 28.23 |
Price/FCF | 16 |
EV/R | 12.69 |
EV/Ebitda | 25.20 |
PEG | 1.61 |
Novo Nordisk A/S (NVO) share price today is $103.275
Yes, Indians can buy shares of Novo Nordisk A/S (NVO) on Vested. To buy Novo Nordisk A/S from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Novo Nordisk A/S (NVO) via the Vested app. You can start investing in Novo Nordisk A/S (NVO) with a minimum investment of $1.
You can invest in shares of Novo Nordisk A/S (NVO) via Vested in three simple steps:
The 52-week high price of Novo Nordisk A/S (NVO) is $147.59. The 52-week low price of Novo Nordisk A/S (NVO) is $99.42.
The price-to-earnings (P/E) ratio of Novo Nordisk A/S (NVO) is 36.1237
The price-to-book (P/B) ratio of Novo Nordisk A/S (NVO) is 28.23
The dividend yield of Novo Nordisk A/S (NVO) is 1.34%
The market capitalization of Novo Nordisk A/S (NVO) is $486.49B
The stock symbol (or ticker) of Novo Nordisk A/S is NVO